Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.53 |
| ▸ | TDO2 | P48775 | 3/20 | 0.53 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.53 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570757 | 0.79 | IDO1 (0.57) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL7988503 | 0.79 | IDO1 (0.57) | IDO1TDO2IDO2ACP3TSHR | |
| 2-Chlorophenyl-Bisphenylmethane(Major) SCHEMBL41575 | 0.78 | IDO1 (0.55) | IDO1TDO2IDO2ACP3TSHR | |
| Hydrochloric Acid SCHEMBL11880995 | 0.77 | IDO1 (0.58) | IDO1TDO2IDO2ACP3TSHR | |
| 2-Chlorophenyl-Bisphenylmethane(Major) SCHEMBL29279416 | 0.76 | IDO1 (0.57) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL521541 | 0.76 | IDO1 (0.53) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL29901560 | 0.76 | IDO1 (0.53) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL17071830 | 0.74 | IDO1 (0.52) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL477580 | 0.74 | ACP3 (0.53) | IDO1TDO2IDO2ACP3TSHR | |
| SCHEMBL477602 | 0.74 | ACP3 (0.53) | IDO1TDO2IDO2ACP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| EP-1648468-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2008-09-24 | — | — | EP | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| CN-1860114-A | Benzoxazinone-derived sulfonamide compounds, process for their preparation and their use as pharmaceuticals | ESTEVE LABOR DR (ES) | 2006-11-08 | — | — | CN | disclosed |
| EP-1660131-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-31 | — | — | EP | disclosed |
| EP-1648468-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005014000-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014045-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | IDO1 2071/4885TDO2 3000/4885IDO2 2088/4885 |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | IDO1 1214/4885TDO2 482/4885IDO2 1282/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | IDO1 2071/4885TDO2 3000/4885IDO2 2088/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | IDO1 2502/4885TDO2 3246/4885IDO2 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.